Differences in the antinociceptive effects of serotonin-noradrenaline reuptake inhibitors via sodium channel blockade using the veratrine test in mice.
Journal
Neuroreport
ISSN: 1473-558X
Titre abrégé: Neuroreport
Pays: England
ID NLM: 9100935
Informations de publication
Date de publication:
09 06 2021
09 06 2021
Historique:
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
27
1
2022
Statut:
ppublish
Résumé
Antidepressants exert their analgesic effects by inhibiting the reuptake of noradrenaline. Several antidepressants have been shown to block the sodium channels, which might contribute to their analgesic potency. The aim of this study was to determine whether serotonin-noradrenaline reuptake inhibitors (SNRIs) could produce antinociceptive effects via sodium channel blockade using the veratrine test in mice. Furthermore, the effects of these agents on the veratrine test were examined to elucidate the effects of several antidepressants and tramadol on sodium channels. The administration of duloxetine (10 mg/kg) and venlafaxine (30 mg/kg) suppressed cuff-induced mechanical allodynia; however, these antinociceptive effects were only partially suppressed by atipamezole. Furthermore, duloxetine and venlafaxine demonstrated antinociceptive effects via sodium channel blockade, as assayed by the veratrine test. In addition, several antidepressants, including amitriptyline, paroxetine and mirtazapine, reduced veratrine-induced nociception. In contrast, milnacipran and tramadol did not alter the veratrine-induced nociception. These results indicated that, in addition to the primary action of SNRIs on monoamine transporters, sodium channel blockade might be involved in the antinociceptive activities of duloxetine and venlafaxine, but not milnacipran.
Identifiants
pubmed: 33994525
doi: 10.1097/WNR.0000000000001658
pii: 00001756-202106020-00006
doi:
Substances chimiques
Serotonin and Noradrenaline Reuptake Inhibitors
0
Sodium Channel Blockers
0
Venlafaxine Hydrochloride
7D7RX5A8MO
Duloxetine Hydrochloride
9044SC542W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
797-802Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: review of the Canadian Pain Society consensus statement. Can Fam Physician. 2017; 63:844–852.
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al.; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309:1359–1367.
Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003; 60:1284–1289.
Sullivan MJL, Reesor K, Mikail S, Fisher R. The treatment of depression in chronic low back pain: review and recommendations. Pain. 1992; 50:5–13.
Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017; 18:E2483.
Emery EC, Luiz AP, Wood JN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets. 2016; 20:975–983.
Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain. 2007; 8:315–324.
Horishita T, Yanagihara N, Ueno S, Okura D, Horishita R, Minami T, et al. Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol. 2017; 390:1255–1270.
Yoshizawa K, Arai N, Suzuki Y, Nakamura T, Takeuchi K, Sakamoto R, et al. Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse. 2018; 72:e22056.
Rogers M, Tang L, Madge DJ, Stevens EB. The role of sodium channels in neuropathic pain. Semin Cell Dev Biol. 2006; 17:571–581.
Benbouzid M, Pallage V, Rajalu M, Waltisperger E, Doridot S, Poisbeau P, et al. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. Eur J Pain. 2008; 12:591–599.
Yoshizawa K, Arai N, Suzuki Y, Fujita A, Takahashi Y, Kawano Y, Hanawa T. Synergistic antinociceptive activity of tramadol/acetaminophen combination mediated by μ-opioid receptors. Biol Pharm Bull. 2020; 43:1128–1134.
Kremer M, Yalcin I, Goumon Y, Wurtz X, Nexon L, Daniel D, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline. J Neurosci. 2018; 38:9934–9954.
Matsuzawa-Yanagida K, Narita M, Nakajima M, Kuzumaki N, Niikura K, Nozaki H, et al. Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology. 2008; 33:1952–1965.
Sikka P, Kaushik S, Kumar G, Kapoor S, Bindra VK, Saxena KK. Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazapine) and their interaction with morphine and naloxone in mice. J Pharm Bioallied Sci. 2011; 3:412–416.
Suzuki T, Ueta K, Tamagaki S, Mashimo T. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg. 2008; 106:1309–1315.
Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev. 2015; 2015:CD011789.
Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, et al. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J. 1984; 107:1058–1065.
Roggen H, Kehler J, Stensbøl TB, Hansen T. Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. Bioorg Med Chem Lett. 2007; 17:2834–2837.
Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001; 7:249–264.
Enomoto T, Yamashita A, Torigoe K, Horiuchi H, Hirayama S, Nakahara K, et al. Effects of mirtazapine on sleep disturbance under neuropathic pain-like state. Synapse. 2012; 66:483–488.
Economos G, Lovell N, Johnston A, Higginson IJ. What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review. Support Care Cancer. 2020; 28:1597–1606.
Huang CJ, Harootunian A, Maher MP, Quan C, Raj CD, McCormack K, et al. Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol. 2006; 24:439–446.
Yamashita T, Yamamoto S, Zhang J, Kometani M, Tomiyama D, Kohno K, et al. Duloxetine inhibits microglial P2X4 receptor function and alleviates neuropathic pain after peripheral nerve injury. PLoS One. 2016; 11:e0165189.